ERC000011
ENA-CHECKLIST
2022-08-11T16:15:01Z
ENA-FIRST-PUBLIC
2022-08-11T16:15:01Z
ENA-LAST-UPDATE
SAMEA14107246
External Id
UNIVERSITY OF MANCHESTER
INSDC center name
2022-08-11T16:15:01Z
INSDC first public
2022-08-11T16:15:01Z
INSDC last update
public
INSDC status
ERS11710323
SRA accession
E-MTAB-11653:Sample 40
Submitter Id
80
year
age
ArrayExpress
broker name
leukocyte
cell_type
Ruxolitinib treatment
clinical history
human
common name
Protocols: Use of human tissue was in compliance with the ethical and legal framework of the Human Tissue Act. Experiments had ethical approval from the NRES committee of the regional NHS health research authority (14/LO/0489 and 17/LO/0888). Primary JAK2 V617F positive samples were obtained from the Manchester Cancer Research Centre Biobank (HTA 30004) following authorisation by the Tissue Biobank’s scientific sub-committee. Patient details are outlined in Table 1. The CD34+ cell population was enriched using CliniMACS (Miltenyi Biotec) according to standard protocols. CD34+ cells were isolated from the peripheral blood of seven patients with myelofibrosis. Cells were cultured for 24 hours in Fishers 20% HS, 10ng/ml IL-3 10ng/ml Flt3, 50ng/ml SCF with either 100nM CBL0137 or carrier control before extraction of RNA. Qiagen RNeasy Plus kit. TruSeq Stranded mRNA assay (Illumina)
description
adult
developmental stage
myelofibrosis
disease
JAK2 V617F
genotype
CD34+
immunophenotype
6
individual
Homo sapiens
organism
Homo sapiens
organism
blood
organism part
Homo sapiens
scientific_name
female
sex
Sample 40
title